---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-229770"
form_type: "8-K"
ticker: "BHC"
cik: "0000885590"
company_name: "Bausch Health Companies Inc."
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:42:30.790766+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb provides financial details for planned acquisition of Novartis eye-care assets

## Summary
- Deal: $1.75B upfront plus up to $750M milestones for Xiidra, AcuStream, SAF312, OJL332.
- Acquired assets generated $487M net revenue in 2022 and $468M in 2021.
- Acquisition expected to close at or around end of September 2023, subject to conditions.
- Audited and unaudited abbreviated financial statements of acquired assets furnished as exhibits.

## SEC filing metadata
- accession: 0001193125-23-229770
- form_type: 8-K
- ticker: BHC
- cik: 0000885590
- company_name: Bausch Health Companies Inc.
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885590/000119312523229770/0001193125-23-229770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885590/000119312523229770/d547838d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-229770
- JSON: https://secwatch.observer/filing/0001193125-23-229770.json
- Plain text: https://secwatch.observer/filing/0001193125-23-229770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.